Tivozanib (AV-951): Potent and Selective VEGFR Inhibitor for Cancer Research

Executive Summary: Tivozanib (AV-951) is a quinoline-urea derivative and second-generation, highly selective VEGFR inhibitor with picomolar potency for VEGFR-2 (IC₅₀=160 pM) and nanomolar activity against PDGFRβ and C-KIT. Compared to first-generation tyrosine kinase inhibitors (TKIs) like sunitinib or sorafenib, it demonstrates improved selectivity and reduced off-target effects, supporting its use in anti-angiogenic and combination cancer therapy (Schwartz 2022, DOI). In clinical studies, Tivozanib achieved a median progression-free survival (PFS) of 12.7 months in metastatic renal cell carcinoma (RCC) patients. Its robust solubility in DMSO (≥22.75 mg/mL) and stable handling conditions (store at -20°C) make it suitable for in vitro drug response assays and combinatorial research. APExBIO supplies Tivozanib (A2251), validated for research-grade applications (product page).

Biological Rationale

Tivozanib (AV-951) targets the vascular endothelial growth factor receptor (VEGFR) family, which includes VEGFR-1, VEGFR-2, and VEGFR-3. These receptors are critical mediators of angiogenesis in both physiological and pathological contexts, especially in solid tumor growth and metastasis (Schwartz 2022). Overexpression and hyperactivation of VEGF signaling are common features in malignancies such as renal cell carcinoma and ovarian carcinoma. Inhibition of these pathways reduces tumor vascularization, limits nutrient supply, and impedes metastatic dissemination. Tivozanib’s high selectivity for VEGFRs, combined with limited activity on unrelated kinases, minimizes off-target toxicity and enhances anti-tumor efficacy.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a quinoline-urea derivative that exerts its effect by competitively inhibiting the ATP-binding sites of VEGFR-1, VEGFR-2, and VEGFR-3. The inhibitory constants (IC₅₀) for VEGFR-2 are as low as 160 pM, which surpasses the potency of other clinically used VEGFR inhibitors (APExBIO). In cell-based assays, Tivozanib also suppresses phosphorylation of PDGFRβ and C-KIT at nanomolar concentrations, but exhibits low c-KIT inhibition compared to less selective TKIs. This precise inhibition of VEGFR-mediated tyrosine kinase signaling disrupts downstream pathways critical for endothelial cell proliferation, migration, and survival, ultimately resulting in reduced angiogenesis and tumor growth (Schwartz 2022).

Evidence & Benchmarks

• Tivozanib inhibits VEGFR-2 kinase activity with an IC₅₀ of 160 pM, demonstrating 10- to 100-fold higher potency than sunitinib, sorafenib, or pazopanib (APExBIO).
• In RCC xenograft models, Tivozanib significantly reduced tumor volume compared to vehicle and other VEGFR inhibitors (Schwartz 2022).
• Phase III clinical trials in metastatic RCC reported a median progression-free survival (PFS) of 12.7 months for Tivozanib-treated patients, compared to 9.1 months for those on sorafenib (Schwartz 2022).
• Tivozanib demonstrates minimal off-target activity, with low c-KIT inhibition and negligible effects on unrelated kinases (APExBIO).
• In ovarian carcinoma cell lines, Tivozanib synergizes with EGFR inhibitors to enhance apoptosis and inhibit proliferation in vitro (Schwartz 2022).

Compared to previous reviews, this article details solubility, workflow, and limits for robust in vitro deployment.

Applications, Limits & Misconceptions

Tivozanib is validated as a research tool for investigating VEGFR signaling, angiogenesis inhibition, and as a benchmark in cell proliferation and apoptosis assays. Its high potency and selectivity make it suitable for studies in renal cell carcinoma and other solid tumor models. Tivozanib is commonly used at 10 μM for 48 hours in cell-based experiments, enabling precise assessment of VEGFR pathway inhibition (APExBIO).

Common Pitfalls or Misconceptions

• Not water soluble: Tivozanib is insoluble in water; DMSO or ethanol with warming must be used for stock solutions (APExBIO).
• Inappropriate long-term storage: Prepared solutions are unstable for extended periods and should be used promptly after preparation.
• Not a pan-kinase inhibitor: It does not broadly inhibit kinases beyond VEGFR, PDGFRβ, and C-KIT at research-use concentrations (Schwartz 2022).
• Not effective in VEGFR-independent tumors: Efficacy is limited in models lacking functional VEGF signaling.
• Dose-dependent effects: Exceeding recommended concentrations can produce off-target toxicity or misleading assay results.

For a workflow-focused discussion, see this article, which offers scenario-driven Q&A on Tivozanib in cytotoxicity and proliferation assays; the present review clarifies clinical and mechanistic boundaries.

Workflow Integration & Parameters

Tivozanib (A2251) is provided as a solid by APExBIO. The recommended stock concentration is ≥22.75 mg/mL in DMSO and ≥2.68 mg/mL in ethanol with gentle warming. Working solutions for cell-based assays should be freshly prepared and used within hours to ensure stability. For cell proliferation or apoptosis assays, a typical final concentration is 10 μM, with treatment durations of 24–72 hours depending on cell type and endpoint (Schwartz 2022). Storage at -20°C is required for bulk compound. Solubility can be enhanced by ultrasonic treatment and gentle warming; avoid repeated freeze-thaw cycles. For more on workflow and translational context, see this perspective, which complements the present article by detailing scenario-driven integration into anti-angiogenic therapy studies.

Conclusion & Outlook

Tivozanib (AV-951) is a next-generation, highly selective VEGFR inhibitor with robust anti-angiogenic and anti-tumor activity in preclinical and clinical settings. Its superior selectivity and potency enable rigorous mechanistic and translational oncology research, especially in renal cell carcinoma and combinatorial therapy scenarios. For detailed protocols, refer to the APExBIO product page. Ongoing research is expected to further define its role in multi-targeted cancer strategies and precision medicine workflows.